Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00694057 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Harbor Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
NCT00694057: Completed Phase 2 study, sponsored by Harbor Therapeutics.
NCT00694057 is a Phase 2 study that has completed, run by Harbor Therapeutics. The registered enrollment target is 164 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00694057, a Phase 2 study, has completed, sponsored by Harbor Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
Study Summary
This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or placebo) for a treatment period of 12-weeks.
Interventions
- DRUG Placebo
- DRUG HE3286
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00694057 record still lists
NCT00694057 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00694057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00694057 about?
NCT00694057 is a clinical study titled "Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus". This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or placebo) for a treatment period of 12-we...
What is the current status of trial NCT00694057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2008-06. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00694057?
The interventions under investigation include: Placebo (DRUG), HE3286 (DRUG).
Who is sponsoring clinical trial NCT00694057?
This trial is sponsored by Harbor Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00694057's enrollment target sits among peer trials
164 413th of 2000 higher than 1,583 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia